NeoGenomics (NEO) to Release Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is expected to be releasing its earnings data before the market opens on Tuesday, February 18th. Analysts expect NeoGenomics to post earnings of $0.03 per share and revenue of $173.40 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

NeoGenomics Trading Up 0.4 %

NASDAQ NEO opened at $13.51 on Tuesday. The stock has a market cap of $1.73 billion, a P/E ratio of -22.15 and a beta of 1.23. NeoGenomics has a fifty-two week low of $12.13 and a fifty-two week high of $19.11. The stock has a 50 day simple moving average of $16.09 and a two-hundred day simple moving average of $15.66. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.

Analysts Set New Price Targets

A number of research firms recently issued reports on NEO. Bank of America increased their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Friday, January 10th. The Goldman Sachs Group reduced their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Jefferies Financial Group started coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Benchmark downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Insiders Place Their Bets

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares of the company’s stock, valued at $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.